Refractory Lupus Nephritis (RLN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Lupus nephritis (LN) is a significant and common complication of systemic lupus erythematosus (SLE) that significantly impacts patients’ well-being and survival. In adults with SLE, up to 60% experience varying degrees of renal disease during their illness. Despite advances in treatment, including the use of corticosteroids and immunosuppressive drugs like cyclophosphamide (CYP) and mycophenolate mofetil (MMF), a notable percentage of LN patients, ranging from 20% to 70%, do not respond well to standard immunosuppressive therapy. When patients with LN fail to achieve clinical remission after appropriate induction immunosuppressive treatment, it is termed refractory lupus nephritis, significantly raising the risk of advancing to end-stage kidney disease and death. Molecular biomarkers show promise as potential substitutes for kidney biopsies in predicting renal outcomes and long-term prognosis. However, the key factor of medication adherence can distinguish between refractory (or resistant) LN and relapsing LN, with the latter being much more common. Almost half of patients with proliferative LN who initially achieve complete remission with immunosuppressive therapy will experience a relapse or renal flare after reducing or stopping their immunosuppressive medication. Other factors contributing to treatment resistance include genetic predisposition and comorbidities such as hypertension, diabetic nephropathy, and antiphospholipid antibodies, all of which require effective management in the overall care of these patients. Several elements can lead to refractory LN, including issues with medication adherence, tolerability of therapy, and adverse events. Late diagnosis, when irreversible damage has already occurred, is another potential contributor to refractory disease. Geographic, genetic, and other epidemiological factors influence how patients respond to treatment and their renal outcomes, and there is still variability in the initial treatment choices. The EULAR/ERA-EDTA recommendations propose switching from either cyclophosphamide (CYC) to mycophenolate mofetil (MMF) or vice versa in cases of refractory disease.

Thelansis’s “Refractory Lupus Nephritis (RLN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Refractory Lupus Nephritis (RLN) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Refractory Lupus Nephritis (RLN) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Refractory Lupus Nephritis (RLN) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Refractory Lupus Nephritis (RLN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033